Leverkusen start planning for Alonso's exit with Real Madrid manager under consideration
According to a recent report from SPORT, it appears that Bayer Leverkusen will not let Xabi Alonso leave for Real Madrid for nothing, as they will expect something in return.
The German side is reportedly eyeing Alvaro Arbeloa, Real Madrid's youth team coach, as a potential replacement for Alonso.
Advertisement
With Carlo Ancelotti's departure all but confirmed, Real Madrid have set their sights on Alonso as the frontrunner for the managerial role.
Alonso's ties to the club and his growing success at Leverkusen have made him a prime candidate. However, the situation has become more intriguing with Arbeloa's name now being linked to Leverkusen as a potential successor to Alonso.
Arbeloa's potential and Madrid's plan
Arbeloa, a former Real Madrid player and current Castilla coach, is part of a shortlist of potential candidates being considered by Bayer Leverkusen, alongside Erik Ten Hag, Cesc Fabregas, and Xavi Hernandez.
Advertisement
While Ten Hag is said to be the favourite for the position, Arbeloa's name has generated significant attention.
Alvaro Arbeloa is on Bayer Leverkusen's radar. (Photo by)
The Spaniard, who played alongside Alonso during their time at Madrid, has already made a positive impact with Real Madrid's youth team.
Real Madrid will not let him leave
Despite Leverkusen's interest, Real Madrid have no plans to part with Arbeloa anytime soon. The club sees him as an important part of their future and intends for him to take further steps within the club.
It is likely that Arbeloa will continue to coach Castilla next season, with a potential future promotion to the first team once Raul Gonzalez's time comes to an end.
Advertisement
Real Madrid have high hopes for Arbeloa's long-term future at the club, envisioning him one day taking the reins of the senior team.
However, the club also understands that Arbeloa's path to that position requires patience. For now, he's viewed as a club man, gradually gaining experience while waiting for his opportunity.
As for Alonso, the former midfielder continues to focus on his current responsibilities at Bayer Leverkusen. Despite the growing speculation surrounding his future, Alonso has insisted on staying calm and not rushing into decisions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why BioNTech Stock Soared Today
BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327. BioNTech has moved the drug into phase 3 trials, and now Bristol will help to fund further trials. Cash payments to BioNTech could exceed $11 billion over time. 10 stocks we like better than BioNTech Se › BioNTech (NASDAQ: BNTX), one of the companies made famous for its role developing vaccines with Pfizer (NYSE: PFE) during the COVID-19 pandemic, soared 20.2% through 12:50 p.m. Monday on news entirely unrelated to COVID. The German biotech announced this morning it is partnering with pharmaceuticals giant Bristol Myers Squibb (NYSE: BMY) to "co-develop and co-commercialize" BioNTech's drug candidate BNT327 as an immunotherapy against multiple kinds of cancer. BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is already involved in "multiple" ongoing clinical trials, including an advanced phase 3 trial testing its usefulness in treating breast cancer and both small cell and non-small cell lung cancer. BioNTech CEO Dr. Uğur Şahin expressed the belief that "BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumor indications." Bristol CEO Christopher Boerner agreed that BNT327 has "significant potential for transforming the standard of care for patients with solid tumors." There are more immediate benefits for BioNTech stock, beginning with Bristol Myers Squibb paying BioNTech $1.5 billion up front for the rights to team up and a further $2 billion in noncontingent payments through 2028 as drug development continues. Additional developmental, regulatory, and commercial milestones, which are contingent on successful development, could add a further $7.6 billion to BioNTech's balance sheet over time. With its lucrative COVID days behind it, BioNTech reported nearly $690 million in losses last year and turned free-cash-flow negative. A tidal wave of cash from Bristol Myers Squibb could really come in handy right about now. Before you buy stock in BioNTech Se, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and BioNTech Se wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. Why BioNTech Stock Soared Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Jack Draper vs Carlos Alcaraz start time and how to watch Italian Open match
Jack Draper and Carlos Alcaraz collide in a tasty quarter-final as they look to roll on at the Italian Open. Draper has climbed into the world's top five and has a solid recent record against the Spaniard, winning two of their last three meetings, including on his way to Indian Wells success earlier this year. Advertisement The pair are yet to meet on clay, though, with Alcaraz possessing such prowess on the surface though he was given a fright by Karen Khachanov in his last outing. The British No 1, meanwhile, had to overcome the unorthodox Corentin Moutet, fighting back to take the last-16 match and set up this encounter in Rome. Here's everything you need to know. When is Jack Draper vs Carlos Alcaraz? Jack Draper vs Carlos Alcaraz will take place on Wednesday 14 May at the Italian Open. The quarter-final is the second match scheduled on Campo Centrale, and will follow the conclusion of Coco Gauff vs Mirra Andreeva - though will not start before 2pm BST. How can I watch it? Viewers in the United Kingdom can watch all of the action from the Italian Open live on Sky Sports, with coverage throughout the tournament. A live stream will be available via Sky Go. Order of play - Wednesday 14 May Campo Centrale (from 12pm BST) Advertisement Coco Gauff (4) vs Mirra Andreeva (7) not before 2pm Jack Draper (5) vs Carlos Alcaraz (3) not before 6pm Aryna Sabalenka (1) vs Qinwen Zheng (8) not before 7.30pm Lorenzo Musetti (8) vs Alexander Zverev (2)
Yahoo
an hour ago
- Yahoo
NATO to ramp up defence plans amid ongoing Russian threat
NATO is planning to significantly expand its military capabilities to strengthen deterrence and defence against the continued threat from Russia, with plans to boost existing targets by about 30%, dpa has learned from alliance sources. The new objectives include increasing stockpiles of long-range cruise missiles and drones, as well as strengthening air defence and artillery systems, according to sources. To meet these goals, NATO member states are expected to receive updated national planning targets, according to the information. The targets are due to be formally adopted at a meeting of NATO defence ministers in Brussels on Thursday. However, reaching the new targets will be challenging, with senior military officials saying member states are already falling about 30% short of existing goals. The exact national targets remain classified, though some details are expected to be released after Thursday's meeting. In Germany, military sources estimate that the Bundeswehr, as the German armed forces are called, may need to grow by a high five-digit number from its current size of around 182,000 troops to meet requirements. Significant investments in air defence systems are also expected.
